Representative before the EPO

Technology company logo thumb
no operation time available
Technology Company

Dörte Klostermeyer-Rauber has worked on the following 30 EPO patent applications which have been published in the last five years:

EP12759084

N-(5-CYCLOALKYL- OR 5-HETEROCYCLYL-)-PYRIDIN-3-YL CARBOXAMIDES

IPC classification:
A61K 31/465, A61K 31/4965, A61P 9/00, C07D 213/74, C07D 401/12, C07D 413/12
Applicant:
F. Hoffmann-La Roche AG
Agent:
Dörte Klostermeyer-Rauber, F. Hoffmann-La Roche AG
Status:
PATENT GRANTED
EP12756212

5-CYCLOALKYL- OR 5-HETEROCYCLYL-NICOTINAMIDES

IPC classification:
A61K 31/4412, A61P 9/00, C07D 213/82, C07D 401/12, C07D 413/12, C07D 417/12
Applicant:
F. Hoffmann-La Roche AG
Agent:
Dörte Klostermeyer-Rauber, F. Hoffmann-La Roche AG
Status:
NO OPPOSITION FILED WITHIN TIMELIMIT
EP12754017

3 -PYRIDINE CARBOXYLIC ACID HYDRAZIDES AS HDL-CHOLESTEROL RAISING AGENTS

IPC classification:
A61K 31/44, A61K 31/443, A61K 31/4439, A61K 31/444, C07D 213/87, C07D 401/06, C07D 405/04, C07D 413/12, C07D 413/14, C07D 417/12
Applicant:
F. Hoffmann-La Roche AG
Agent:
Dörte Klostermeyer-Rauber, F. Hoffmann-La Roche AG
Status:
APPLICATION DEEMED TO BE WITHDRAWN
EP12840084

ANTI-HtrA1 ANTIBODIES AND METHODS OF USE

IPC classification:
A61K 39/395, A61P 27/02, C07K 16/00
Applicant:
F. Hoffmann-La Roche AG
Agent:
Dörte Klostermeyer-Rauber, F. Hoffmann-La Roche AG
Status:
EXAMINATION IN PROGRESS
EP12775028

1-CYCLOALKYL- OR 1-HETEROCYCLYL-HYDROXYIMINO-3-PHENYL-PROPANES

IPC classification:
A61K 31/15, A61K 31/35, A61K 31/382, A61K 31/445, A61K 31/45, A61P 3/10, C07C 251/42, C07C 317/32, C07D 211/40, C07D 309/06, C07D 335/02
Applicant:
F. Hoffmann-La Roche AG
Agent:
Dörte Klostermeyer-Rauber, F. Hoffmann-La Roche AG
Status:
GRANT OF PATENT INTENDED
EP12784005

1-PYRIDAZINYL-HYDROXYIMINO- 3- PHENYL- PROPANES AS GPBAR1 AGONISTS

IPC classification:
A61K 31/50, A61P 3/10, C07D 237/08
Applicant:
F. Hoffmann-La Roche AG
Agent:
Dörte Klostermeyer-Rauber, F. Hoffmann-La Roche AG
Status:
NO OPPOSITION FILED WITHIN TIMELIMIT
EP13746304

COMPOSITIONS AND METHODS FOR USING CSF1R INHIBITORS

IPC classification:
A61K 39/395, A61P 19/02, C07K 16/24
Applicant:
F. Hoffmann-La Roche AG
Agent:
Dörte Klostermeyer-Rauber, F. Hoffmann-La Roche AG
Status:
EXAMINATION IN PROGRESS
EP13707658

ANTI-P-SELECTIN ANTIBODY FORMULATION

IPC classification:
A61K 9/00, A61K 47/10, A61K 47/18, A61K 47/26, C07K 16/28
Applicant:
F. Hoffmann-La Roche AG
Agent:
Dörte Klostermeyer-Rauber, F. Hoffmann-La Roche AG
Status:
APPLICATION DEEMED TO BE WITHDRAWN
EP12802488

PCSK9-BINDING POLYPEPTIDES AND METHODS OF USE

IPC classification:
A61K 31/22, A61K 31/40, A61K 38/17, A61K 38/18, A61K 39/00, A61K 39/395, A61K 45/06, A61P 3/06, A61P 9/10, C07K 14/485, C07K 14/705, C07K 16/40, C07K 19/00, C12N 9/64, C12N 15/63
Applicant:
F. Hoffmann-La Roche AG
Agent:
Dörte Klostermeyer-Rauber, F. Hoffmann-La Roche AG
Status:
APPLICATION DEEMED TO BE WITHDRAWN
EP13713197

1,2- PYRIDAZINE, 1,6- PYRIDAZINE OR PYRIMIDINE - BENZAMIDE DERIVATIVES AS GPBAR1 MODULATORS

IPC classification:
A61K 31/50, A61K 31/505, A61P 3/00, A61P 29/00, C07D 237/20, C07D 239/42, C07D 401/04
Applicant:
F. Hoffmann-La Roche AG
Agent:
Dörte Klostermeyer-Rauber, F. Hoffmann-La Roche AG
Status:
NO OPPOSITION FILED WITHIN TIMELIMIT
EP13733479

ANTI-PCSK9 ANTIBODIES, FORMULATIONS, DOSING, AND METHODS OF USE

IPC classification:
A61K 39/395, C07K 16/40
Applicant:
F. Hoffmann-La Roche AG
Agent:
Dörte Klostermeyer-Rauber, F. Hoffmann-La Roche AG
Status:
APPLICATION DEEMED TO BE WITHDRAWN
EP11725930

REVERSED PHASE HPLC PURIFICATION OF A GLP-1 ANALOGUE

IPC classification:
C07K 14/605
Applicant:
F. Hoffmann-La Roche AG
Agent:
Dörte Klostermeyer-Rauber, F. Hoffmann-La Roche AG
Status:
APPLICATION DEEMED TO BE WITHDRAWN
EP13802836

RON COMPOSITIONS AND METHODS OF USE THEREOF

IPC classification:
A61K 39/395, C07K 14/52, C07K 16/28, C12N 5/10
Applicant:
F. Hoffmann-La Roche AG
Agent:
Dörte Klostermeyer-Rauber, F. Hoffmann-La Roche AG
Status:
EXAMINATION IN PROGRESS
EP14776479

FORMULATIONS WITH REDUCED OXIDATION

IPC classification:
A61K 38/18, A61K 39/395
Applicant:
F. Hoffmann-La Roche AG
Agent:
Dörte Klostermeyer-Rauber, F. Hoffmann-La Roche AG
Status:
EXAMINATION IN PROGRESS
EP11808100

ANTI-PCSK9 ANTIBODIES AND METHODS OF USE

IPC classification:
A61K 39/395, C07K 16/40
Applicant:
F. Hoffmann-La Roche AG
Agent:
Dörte Klostermeyer-Rauber, F. Hoffmann-La Roche AG
Status:
APPLICATION DEEMED TO BE WITHDRAWN
EP14773506

FORMULATIONS WITH REDUCED OXIDATION

IPC classification:
A61K 38/18, A61K 39/395
Applicant:
F. Hoffmann-La Roche AG
Agent:
Dörte Klostermeyer-Rauber, F. Hoffmann-La Roche AG
Status:
EXAMINATION REQUESTED
EP11796899

TREATMENT OF HER2-POSITIVE CANCER WITH PACLITAXEL AND TRASTUZUMAB-MCC-DM1

IPC classification:
A61K 31/337, A61K 39/395, A61P 35/00
Applicant:
F. Hoffmann-La Roche AG
Agent:
Dörte Klostermeyer-Rauber, F. Hoffmann-La Roche AG
Status:
APPLICATION DEEMED TO BE WITHDRAWN
EP11771080

N-PYRIDIN-3-YL OR N-PYRAZIN-2-YL CARBOXAMIDES

IPC classification:
C07D 213/75, C07D 401/12, C07D 403/12, C07D 405/12, C07D 407/12, C07D 413/12, C07D 417/12, C07D 498/04
Applicant:
F. Hoffmann-La Roche AG
Agent:
Dörte Klostermeyer-Rauber, F. Hoffmann-La Roche AG
Status:
PATENT GRANTED
EP14780964

METHODS OF USING ANTI-LGR5 ANTIBODIES

IPC classification:
A61K 31/015, A61K 39/395, A61P 35/00, C07K 16/30
Applicant:
F. Hoffmann-La Roche AG
Agent:
Dörte Klostermeyer-Rauber, F. Hoffmann-La Roche AG
Status:
EXAMINATION IN PROGRESS
EP11730660

1-HYDROXYIMINO-3-PHENYL-PROPANES

IPC classification:
C07C 251/48, C07D 213/53, C07D 213/55, C07D 213/64, C07D 213/89, C07D 215/12, C07D 239/26, C07D 241/12
Applicant:
F. Hoffmann-La Roche AG
Agent:
Dörte Klostermeyer-Rauber, F. Hoffmann-La Roche AG
Status:
NO OPPOSITION FILED WITHIN TIMELIMIT
EP11752233

HETEROARYLMETHYL AMIDES

IPC classification:
A61K 31/4427, A61K 31/455, A61K 31/506, C07D 213/16, C07D 401/06, C07D 413/08, G01N 33/92
Applicant:
F. Hoffmann-La Roche AG
Agent:
Dörte Klostermeyer-Rauber, F. Hoffmann-La Roche AG
Status:
NO OPPOSITION FILED WITHIN TIMELIMIT
EP11797222

OXIME COMPOUNDS AS HDL-CHOLESTEROL RAISING AGENTS

IPC classification:
A61K 31/465, A61K 31/4965, A61P 9/00, C07D 213/63, C07D 213/74, C07D 241/24
Applicant:
F. Hoffmann-La Roche AG
Agent:
Dörte Klostermeyer-Rauber, F. Hoffmann-La Roche AG
Status:
NO OPPOSITION FILED WITHIN TIMELIMIT
EP15703385

METHODS OF USING ANTI-STEAP1 ANTIBODIES AND IMMUNOCONJUGATES

IPC classification:
A61K 47/48, A61P 35/00
Applicant:
F. Hoffmann-La Roche AG
Agent:
Dörte Klostermeyer-Rauber, F. Hoffmann-La Roche AG
Status:
EXAMINATION REQUESTED
EP15716335

ANTI-OX40 ANTIBODIES AND METHODS OF USE

IPC classification:
C07K 16/28
Applicant:
F. Hoffmann-La Roche AG
Agent:
Dörte Klostermeyer-Rauber, F. Hoffmann-La Roche AG
Status:
EXAMINATION REQUESTED
EP15721059

COMBINATION THERAPY COMPRISING ANTI-ANGIOGENESIS AGENTS AND OX40 BINDING AGONISTS

IPC classification:
A61K 39/395, A61P 35/00, C07K 16/22, C07K 16/28
Applicant:
F. Hoffmann-La Roche AG
Agent:
Dörte Klostermeyer-Rauber, F. Hoffmann-La Roche AG
Status:
EXAMINATION REQUESTED
EP15720875

METHODS OF TREATING EARLY BREAST CANCER WITH TRASTUZUMAB-MCC-DM1 AND PERTUZUMAB

IPC classification:
A61K 39/00, C07K 16/32, A61K 47/50
Applicant:
F. Hoffmann-La Roche AG
Agent:
Dörte Klostermeyer-Rauber, F. Hoffmann-La Roche AG
Status:
EXAMINATION REQUESTED
EP15716824

4-AMINO-IMIDAZOQUINOLINE COMPOUNDS

IPC classification:
A61K 31/4188, A61K 31/437, A61P 31/00, A61P 35/00, A61P 37/02, C07D 471/04
Applicant:
F. Hoffmann-La Roche AG
Agent:
Dörte Klostermeyer-Rauber, F. Hoffmann-La Roche AG
Status:
EXAMINATION REQUESTED
EP15730643

ANTI-LGR5 ANTIBODIES AND USES THEREOF

IPC classification:
A61P 35/00, C07K 16/28, G01N 33/577
Applicant:
F. Hoffmann-La Roche AG
Agent:
Dörte Klostermeyer-Rauber, F. Hoffmann-La Roche AG
Status:
EXAMINATION REQUESTED
EP15822079

METHODS OF TREATING CANCER USING TIGIT INHIBITORS AND ANTI-CANCER AGENTS

IPC classification:
A61K 31/7088, A61K 39/395, A61P 35/00
Applicant:
F. Hoffmann-La Roche AG
Agent:
Dörte Klostermeyer-Rauber, F. Hoffmann-La Roche AG
Status:
EXAMINATION REQUESTED

Please Sign in to use this feature